Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06146608
Other study ID # IRB0147198
Secondary ID 2023-67017-39059
Status Recruiting
Phase
First received
Last updated
Start date January 15, 2023
Est. completion date January 14, 2026

Study information

Verified date March 2024
Source Cornell University
Contact Kimberly O O'Brien, PhD
Phone 607-255-3743
Email koo4@cornell.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The FeMicrobiome study will evaluate gut microbiome features and their relationships with dietary iron absorption in healthy adults. The investigators hypothesize that (1) the gut microbiota can be shaped by the heme and non-heme Fe content of the diet and that (2) this will influence individual variation in dietary Fe absorption.


Description:

Iron is an essential micronutrient ingested as either heme iron (from animal products) or non-heme iron (from both plant and animal sources). Humans have no regulatable means of eliminating absorbed iron, necessitating tight control of dietary iron absorption. Likewise, native microbes have evolved efficient iron sensing and utilization pathways to scavenge iron from the gastrointestinal environment, resulting in a competition for iron between the host and their microbiota. As growing numbers of Americans adopt plant-based diets, heme iron intakes are markedly reduced. This may shift the gut microbiome as some gut microbiota cannot independently synthesize heme and require host dietary heme sources to support their heme-dependent functions. Animal data have recently discovered that other gut microbiota respond to a low iron. To date, significant knowledge gaps exist on the interplay between dietary iron sources, native gut microbes, and iron utilization in humans. In the FeMicrobiome study, study investigators will recruit 120 adults who habitually ingest plant-based diets or habitually ingest diets containing animal protein (e.g., beef, pork, chicken, fish, and seafood). Iron absorption will be measured by using an in vivo, functional approach based on stable iron isotopes (i.e., 57Fe). Study participants will consume 57Fe (as ferrous sulfate) in the fasted state followed by two standardized meals. Two weeks after iron dosing, a blood sample will be collected from each participant and the amount of 57Fe incorporated into red blood cells will be measured using magnetic sector thermal ionization mass spectrometry. A stool sample will be collected near the time of 57Fe consumption. DNA will be extracted from this stool sample and sequenced using a high-depth shotgun metagenomic approach.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date January 14, 2026
Est. primary completion date January 14, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Healthy adults - Age between 18- 40y - Non-smoking - Not currently taking vitamin, mineral, prebiotic, and probiotic supplements. - Females: premenopausal and not pregnant or lactating - No preexisting medical complications (such as eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis) - Body mass index (BMI) between 18 - 27 kg/m2. Exclusion Criteria: - BMI <18 or > 27 kg/m2, - Age <18 y or > 40y, - Not of Northern European or East Asian ancestry - Smoking - Pregnancy, lactating - Have gastrointestinal disorders/malabsorption diseases/hemoglobinopathies/dietary restrictions/steroid use/ medication use of medications known to impact iron status, iron utilization or inflammatory status - Currently take vitamin, mineral, prebiotic, and probiotic supplements. - Recently received antibiotic treatment

Study Design


Locations

Country Name City State
United States Cornell University Ithaca New York

Sponsors (1)

Lead Sponsor Collaborator
Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percent of non-heme iron absorption Percent non-heme iron absorption will be determined by red blood cell iron incorporation of stable 57Fe 2-week
Primary The concentrations of hemoglobin The concentrations of hemoglobin (d/dL) baseline
Primary The concentrations of ferritin The concentrations of ferritin (ug/L) baseline
Primary Serum transferrin receptor Serum transferrin receptor in mg/L baseline
Primary The hematocrit Blood hematocrit in % baseline
Primary Habitual dietary information Habitual dietary information will be obtained from Diet History Questionnaire III. baseline
Primary Dietary information on the day prior to iron dosing Detailed dietary information about all foods and beverages consumed on the day prior to iron dosing will be obtained from the Automated Self-Administered 24-Hour Dietary Assessment Tool. Total iron intake will be presented as a proportion of the daily iron requirement. Total heme and non-heme iron intakes will be quantified. baseline
Primary Gut microbiome composition Shotgun metagenomic sequencing will be performed to assess the gut microbiome compositions and gene functional features in a stool sample collected within one day before or after iron dosing. baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04423237 - Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
Completed NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients Phase 2
Withdrawn NCT03800446 - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood N/A
Not yet recruiting NCT02833493 - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload N/A
Completed NCT02164253 - Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients Phase 2
Completed NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Phase 2
Completed NCT00512226 - Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia N/A
Recruiting NCT00378469 - Study of the Effects of Muscular Activity on Iron Metabolism N/A
Completed NCT00117507 - Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase 4
Completed NCT00138684 - Cytochrome P450 2E1 and Iron Overload Phase 2
Completed NCT03990181 - Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement N/A
Terminated NCT02274233 - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia Phase 1
Active, not recruiting NCT01443195 - Iron Metabolism in Small Pre Term Newborns N/A
Completed NCT01546415 - Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Phase 4
Completed NCT01572818 - Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients N/A
Not yet recruiting NCT00980421 - Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children Phase 3
Completed NCT01047098 - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation N/A
Recruiting NCT05294471 - Fully Automated High-Throughput Quantitative MRI of the Liver
Completed NCT03591575 - Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children Phase 4
Active, not recruiting NCT00907283 - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) Phase 2